Centre

The Centre for Breakthrough Medicines (CBM) is a leading contract development and manufacturing organization (CDMO) specifically designed to accelerate the development and commercialization of advanced therapies. Based in King of Prussia, Pennsylvania, the company provides end-to-end services including process development, plasmid DNA production, viral vector manufacturing, and cell therapy production. CBM operates one of the world's largest single-site cell and gene therapy manufacturing facilities, offering integrated testing and analytical services to streamline the path to clinical trials and market. In 2023, the company was acquired by SK Pharmteco, significantly expanding its global reach and capacity to support life-saving genomic medicines.